本文已被：浏览 728次 下载 778次
投稿时间：2021-01-04 网络发布日期：2021-08-20
投稿时间：2021-01-04 网络发布日期：2021-08-20
中文摘要: 目的 系统评价沙库巴曲缬沙坦钠治疗慢性心力衰竭预后的情况。方法 检索中国知网、维普、万方、Pubmed、Web of Science、Cochrane Library等数据库,检索时间至2020年12月20日,使用Endnote软件筛除重复文献、阅读文献摘要等,用Revman 5.3软件进行偏倚风险评价、敏感性分析以及亚组分析等。结果 本研究纳入9篇文献13 217例患者,Meta分析结果显示,沙库巴曲缬沙坦钠组治疗慢性心力衰竭的再住院率［OR=0.77,95%CI(0.71,0.84),P<0.01］、心血管死亡率［OR=0.81,95%CI(0.73,0.90),P<0.01］、全因死亡率［OR=0.86,95%CI(0.78,0.94),P<0.01］低于ACEI/ARB药物组。两组心血管不良事件发生率比较差异无统计学意义（P=0.33）。结论 沙库巴曲缬沙坦钠可有效降低慢性心力衰竭患者再住院率、心血管死亡率以及全因死亡率,但心血管不良事件未见明显减少。
Abstract:Objective To systematically investigate the prognosis of patients with chronic heart failure (CHF) treated with sacubitril/valsartan sodium.Methods Relevant studies were searched in databases CNKI,VIP,Wanfang,Pubmed,Web of Science,and Cochrane library until December 20,2020.Endnote software was used to screen out duplicate literatures and read literature abstract.Revman 5.3 software was used for bias risk assessment,sensitivity analysis,and subgroup analysis.Results A total of 9 studies (13 217 cases) were included in this analysis.Meta-analysis showed that the rehospitalization rate of the sacubitril/valsartan sodium group for treatment of chronic heart failure ［OR=0.77,95%CI(0.71,0.84),P＜0.01］,cardiovascular mortality ［OR=0.81,95%CI(0.73,0.90),P＜0.01］,all-cause mortality ［OR=0.86,95%CI(0.78,0.94),P＜0.01］ were lower than those of ACEI/ARB group.There was no significant difference in adverse cardiovascular events between two groups (P=0.33).conclusions Sacubitril/valsartan sodium can effectively reduce the rehospitalization rate,cardiovascular mortality and all-cause mortality in patients with chronic heart failure,but no significant reduction in cardiovascular adverse events has been observed.
keywords: Sacubitril/valsartan sodium Heart failure,Chronic Adverse cardiovascular events Meta analysis Prognosis
文章编号： 中图分类号：R541.6 文献标志码：A
基金项目:湖北省教育厅科学技术研究项目(B2018001)
附件
| Author Name | Affiliation |
| ZHAO Rui-yu,YANG Wei,HAN Hong-yan | Department of Cardiology,Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,Hubei 430064， China |
引用文本：
赵瑞毓, 杨威, 韩红彦.沙库巴曲缬沙坦钠治疗慢性心力衰竭预后的Meta分析[J].中国临床研究,2021,34(8):1019-1023.
赵瑞毓, 杨威, 韩红彦.沙库巴曲缬沙坦钠治疗慢性心力衰竭预后的Meta分析[J].中国临床研究,2021,34(8):1019-1023.